Navigation Links
A novel marker of colorectal carcinoma
Date:5/22/2009

The colorectal cancer is thought to be resulted from a combination of environmental factors, diet, lifestyle, chronic inflammation and accumulation of specific genetic alterations. The pathogenesis and development of colorectal cancer involve multi-genes and multi-steps. TSPAN1 (GenBank Accession No. AF065388) is a new member of TM4SF located at chromosome 1 p34.1. It encodes a 241 amino acid protein. TSPAN1 was reported as a tumor-related gene recently.

A research team led by Dr Jian-Wei Zhu from Nantong University, China, investigated the association between TSPAN1 and human colorectal adenocarcinoma. Their study will be published on May 14, 2009 in the World Journal of Gastroenterology

In this study, total RNA was extracted in 20 human adenocarcinoma tissues for TSPAN1 mRNA assay by RT-PCR. Eighty-eight specimens of human colorectal adenocarcinoma were surgically removed. TSPAN1 protein levels in cancer tissues were determined by immunohistochemistry using a polyclonal antibody against self-prepared TSPAN1. The correlation between TSPAN1 expression and the clinicopathological factors and the overall survival rate was analyzed by univariate and multivariate assay.

By RT-PCR assay, it was shown that TSPAN1 mRNA was detected in 90.0% (18/20) of cancerous tissue. The light density of TSPAN1 mRNA expression levels was 0.89 0.30 in adenocarcinoma by gel-image system. TSPAN1 protein expression was detected in 78.41 %( 69/88) and weakly expressed in 40% normal colorectal tissues by immunohistochemistry. There were significant differences between colorectal adenocarcinoma and normal control epithelium (P < 0.05). TSPAN1 protein expression in colorectal cancerous tissue was significantly correlated with the histological grade, cell expression PCNA, lymph nodal metastasis and TNM staging of the disease. Patients with TSPAN1 protein over expression had a significantly shorter survival period than that in patients with TSPAN1 protein negative or weak expression, respectively (P<0.05). Furthermore, by multivariate analysis TSPAN1 protein expression demonstrated an independent prognostic factor for human colorectal cancers (P<0.05, relative risk 0.755; 95% confidence interval 0.302-1.208).

The result indicated that testing TSPAN1 expression in tissues would be a useful tool to evaluate the prognosis of patients with colorectal cancer.


'/>"/>

Contact: Lai-Fu Li
wjg@wjgnet.com
86-105-908-0039
World Journal of Gastroenterology
Source:Eurekalert

Related medicine news :

1. Novel 3-D cell culture model shows selective tumour uptake of nanoparticles
2. Novel virus detection identifies new viruses in study of respiratory infections and asthma attacks
3. Researchers uncover novel mechanism that balances the sizes of functional areas in the brain
4. Novel Cooling Therapy May Have Aided Injured Football Player
5. ECLIPSE data on effects of Otsukas investigational novel treatment, Tolvaptan
6. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
7. GrantAdler Shipping Novel Implantable Vascular Access Port
8. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
9. Novel strategy under study for aggressive leukemia
10. ISTO Technologies Receives 510(k) Clearance for a Novel Bone Graft Substitute and Bone Graft Extender
11. 454 Sequencing(TM): Science Paper Describes a Novel, Highly Efficient Method of Sequencing Ancient DNA; Sequences the Mitochondria of 10 Individual Mammoths to Prove It
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Cranbury, NJ (PRWEB) , ... February 23, 2017 ... ... disease media outlet with a clinician-based audience, will be participating in Rare Disease ... 2017, in Washington, D.C. In addition, Rare Disease Report, a website, weekly e-newsletter ...
(Date:2/23/2017)... ... ... Hamlin Dental Group and Dr. Hamid Reza, dentist in North Hollywood ... of February, patients who visit Hamlin Dental Group will receive a ticket for a ... the Cheesecake Factory. , Tickets are available for routine dental visits and other ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... will host a diverse symposium on “Doping in Sport: How the ... Sheppard Mullin Richter & Hampton LLP. The symposium will be held at Pepperdine ...
(Date:2/23/2017)... ... 2017 , ... ERT, a global data and technology company ... a leading clinical development service provider, has selected ERT’s Trial Oversight suite as ... part to an array of circumstances including the use of multiple data capture ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Center for Autism ... Consortium for Autism Research and Treatment (RI-CART) and Cinemaworld to present Sensory Friendly ... (ASD) to see films in an environment that accommodates their unique needs. , ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... 24 février 2017 ITL Limited, ( ASX : ITD ), ... ravie d,annoncer les excellents résultats semestriels clos le 31 ... Une présentation complète « Résultats et mise à jour sur ... . Faits marquants ... 1,04 million $ ; en hausse de 104 %) ...
(Date:2/24/2017)... 24, 2017 Medivir AB (Nasdaq ... a new Board of Directors that will be submitted ... Committee comprises representatives of the company,s three largest shareholders ... who have accepted a seat on the Nomination Committee, ... the 2016-2017 Nomination Committee was as follows:  ...
(Date:2/23/2017)...  Genesis Healthcare Services has merged with Hospice Cloud, ... Bill Monast , President and CEO of Hospice ... Feltman , executives with Home Health Depot, Inc., the ... This acquisition helps Hospice Cloud maintain its position ... medical equipment (DME) solutions for the hospice industry. ...
Breaking Medicine Technology: